PetVivo Reports Financial and Operational Results for Fiscal 2026
View original at globenewswire.comPetVivo Reports Financial and Operational Results for Fiscal 2026 MINNEAPOLIS, MN, US, June 29, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
PetVivo.ai is the first of its kind, providing a strong first-mover advantage for veterinary clinics.
60% confidenceThe beta group of veterinarians demonstrated a 50% to 90% reduction in veterinary customer acquisition costs, lowering it from a typical $80-$400 per customer to less than $43.
60% confidenceThe public B2C launch of AgenticPet crushed expectations, onboarding 1,000+ active beta users in less than 72 hours.
60% confidenceFiscal 2026 was an exciting year of rapid transformation and platform commercialization, with focus on unique IP in the greatest marketplace opportunities.
60% confidenceGen Zers represent 20% of U.S. pet households, with ownership growing more than 43% annually.
60% confidenceDevelopment and sales teams remained focused on generating strong, high-margin recurring revenue streams to drive the highest valuation for PETV.
60% confidenceSpryng is believed to be the first hydrogel-based intra-articular injectable veterinary medical device to receive regulatory recognition from Health Canada leading to commercialization in the country.
60% confidenceOfficial commercial launch of PetVivo.ai is expected within the next few months, as AI engine training is finalized.
60% confidenceThe U.S. animal health market alone will double to $11.3 billion by 2030, providing strong tailwinds for PetVivo.
60% confidenceAgenticPet's AI-powered diagnosis has an accuracy of 97%.
60% confidenceCanada's animal healthcare market is reportedly growing at a 6.8% CAGR to exceed $4.4 billion by 2031, representing a huge opportunity for PetVivo.
60% confidence